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The ST18 gene has been proposed to act either as a tumor suppressor or as an oncogene in different human cancers, but direct evi-
dence for its role in tumorigenesis has been lacking thus far. Here, we demonstrate that ST18 is critical for tumor progression and
maintenance in a mouse model of liver cancer, based on oncogenic transformation and adoptive transfer of primary precursor cells
(hepatoblasts). ST18 messenger RNA (mRNA) and protein were detectable neither in normal liver nor in cultured hepatoblasts,
but were readily expressed after subcutaneous engraftment and tumor growth. ST18 expression in liver cells was induced by
inflammatory cues, including acute or chronic inflammation in vivo, as well as coculture with macrophages in vitro. Knocking
down the ST18mRNA in transplanted hepatoblasts delayed tumor progression. Induction of ST18 knockdown in pre-established
tumors caused rapid tumor involution associated with pervasive morphological changes, proliferative arrest, and apoptosis in
tumor cells, as well as depletion of tumor-associated macrophages, vascular ectasia, and hemorrhage. Reciprocally, systemic deple-
tion of macrophages in recipient animals had very similar phenotypic consequences, impairing either tumor development or main-
tenance, and suppressing ST18 expression in hepatoblasts. Finally, RNA sequencing of ST18-depleted tumors before involution
revealed down-regulation of inflammatory response genes, pointing to the suppression of nuclear factor kappa B–dependent tran-
scription. Conclusion: ST18 expression in epithelial cells is induced by tumor-associated macrophages, contributing to the recipro-
cal feed-forward loop between both cell types in liver tumorigenesis. Our findings warrant the exploration of means to interfere
with ST18-dependent epithelium–macrophage interactions in a therapeutic setting. (HEPATOLOGY 2016; 00:000-000).
Abbreviations: CSF, colony stimulating factor; CSF-R1, colony stimulating factor 1 receptor; DMEM, Dulbecco’s modified Eagle’s medium; E,
embryonic day; ECCD-1, rat anti-mouse E-cadherin; EGF, epidermal growth factor; FBS, fetal bovine serum; HCC, hepatocellular carcinoma; HGF,
hepatocyte growth factor; IgG, immunoglobulin G; IHC, immunohistochemistry; L1, LINE-1; LPS, lipopolysaccharide; mRNA, messenger RNA; NF-
kB, nuclear factor kappa B; PCR, polymerase chain reaction; PFIC, progressive familial intrahepatic cholestasis; shRNA, short hairpin RNA; TAM,
tumor-associated macrophage.
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ST18 was originally identified as a candidatetumor suppressor in breast cancer, hence itsname (suppression of tumorigenicity 18).(1) Suc-
cessive studies revealed activation of the same gene in
pediatric acute myeloid leukemia(2,3) and hepatocellular
carcinoma (HCC),(4) suggesting an oncogenic function
of ST18. In particular, the mapping of integration sites
of the endogenous retrotransposon LINE-1 (L1) in
HCC led to the identification of 12 tumor-specific L1
insertions, one of which activated ST18.(4)
ST18 (also called NZF-3 or MYT3) is a member of
the NZF/MyT1 family of transcription factors, a non-
classical zinc finger family that includes two other
members, NZF-1 and Myt1, with six C2HC-type fin-
gers arranged in two main clusters, each of which
might in principle bind DNA.(1,5,6) The three genes
are expressed in neural tissue and, based on expression
patterns and overexpression experiments, are involved
in the induction of neuronal differentiation.(7) ST18 is
expressed at low levels in a number of different rat tis-
sues (including liver) and is required for fatty acid– and
cytokine-induced apoptosis in pancreatic b cells.(8)
Finally, RNA interference and messenger RNA
(mRNA) profiling studies in human fibroblasts have
indicated that ST18 regulates proapoptotic and proin-
flammatory genes in response to tumor necrosis factor
a,(5) although the relevance of these regulatory events
in cancer remains unclear.
Here, we unravel a critical role for ST18 in a mouse
model of HCC based on the adoptive transfer of trans-
formed mouse embryonic hepatoblasts.(9) ST18 was
undetectable in either cultured cells or normal livers
but was induced in subcutaneous tumors under the
control of inflammatory cues, and in particular tumor-
associated macrophages (TAMs). Systemic depletion
of macrophages in recipient animals prevented ST18
expression in transformed hepatoblasts and impaired
both tumor development and maintenance. Recipro-
cally, ST18 knockdown in hepatoblasts delayed tumor
progression or, when induced in preformed tumors,
led to rapid tumor involution associated with loss of
TAMs and down-regulation of an inflammatory gene
expression signature. Therefore, ST18 expression in
the epithelial compartment contributes to the tight
connection between inflammation and tumorigenesis
in the liver.(10)
Materials and Methods
ISOLATION, CULTURE,
RETROVIRAL INFECTION,
AND SUBCUTANEOUS
TRANSPLANTATION OF LIVER
PROGENITOR CELLS
We derived hepatoblasts from the two mouse strains
C57/JHsd (Harlan laboratories) and TRP53/C57
(Jackson laboratories), according to a protocol pub-
lished previously.(9) Liver cell suspensions from fetal
livers of embryonic day (E) 14.5-18.5 mice were diced
and treated with Dispase (Gibco, 1000 U/mL) for 1
hour at 378C. The livers were dispersed into single
cells by pipetting and filtrated through a nylon mesh
filter (pore size 100lm). The cellular pellet was washed
with hypotonic lysis buffer (150 mM NH4Cl, 10 mM
KHCO3, 100 lM EDTA) for 3 minutes at 48C, cen-
trifuged, and placed in ice. Purification of E-cadherin
positive hepatoblasts was performed using the MACS
magnetic cell sorting system (Miltenyi) through indi-
rect labeling with the rat anti-mouse E-cadherin
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(ECCD-1) antibody (Calbiochem).(11) Before loading
onto MACS MS size columns, liver cell suspensions
were incubated with the antibody complex for 45
minutes at 48C. Antibody complexes were prepared by
incubating 4 lg of ECCD-1 antibody with 20 lL of
immunomagnetic beads at room temperature for 1
hour. Eluted cells were plated onto laminin-coated
plates (Sigma) in Dulbecco’s modified Eagle’s medium
(DMEM) (Lonza), supplemented with 10% fetal
bovine serum (FBS) NA (HyClone), 1% glutamine
(Euroclone), 1% penicillin/streptomycin (Life Tech-
nologies), hepatocyte growth factor (HGF) (40 ng/
mL, Peprotech), epidermal growth factor (EGF) (20
ng/mL, Peprotech) and dexamethasone (31026 M,
Sigma). After 48 hours, cultured hepatoblasts were
transduced with a combination of retrovirus encoding
for c-myc, oncogenic RAS (H-RasV12), or shp53.
Human hepatocellular liver carcinoma cell line HepG2
(DSMZ) cells were grown in Roswell Park Memorial
Institute 1640 medium (Lonza) supplemented with
10% FBS NA (HyClone), 1% glutamine (Euroclone),
and 1% penicillin/streptomycin (Life Technologies)
under 5% CO2 at 378C.
To generate short hairpin RNA (shRNA) hairpins
targeting both human and mouse ST18, we designed
97 bp oligonucleotides including the desired shRNA
sequences (in a mir-30 format) flanked on either side
by tails complementary to the following polymerase
chain reaction (PCR) primers: XhoI_fw (50- CAG
AAG GCT CGA GAA GGT ATA TTG CTG
TTG ACA GTG AGC G-30) and EcoRI_rv (50-
CTA AAG TAG CCC CTT GAA TTC CGA
GGC AGT AGG CA-30). Amplified PCR products
were digested with XhoI/EcoRI and cloned in the
mir-30 based retroviral vector TtRMPVIR.(12) The
target sequences used in this study were TTCATGCT-
TAAGTCCAATGtg (ST18_1), TTTAAAGACTG-
GATACTGCtg (ST18_6) and TTGATTCAGGAA
ATGGTGGtg (ST18_7). The efficacy of knockdown
was initially tested in 293T cells. Retroviruses were
produced in Phoenix packaging cells and collected in
DMEM (Lonza) supplemented with 10%
tetracycline-free FBS NA (HyClone), 1% glutamine
(Euroclone), and 1% penicillin/streptomycin (Life
Technologies). Supernatant was passed through a
0.45-lm filter and supplemented with polybrene (2
lg/mL, Sigma). The infection procedure was repeated
three times every 4 hours before adding fresh medium
supplemented with HGF (40 ng/mL, Peprotech),
EGF (20 ng/mL, Peprotech), and dexamethasone
(31026 M, Sigma).
For in vivo tumor formation experiments, 3 3 105
genetically modified hepatoblasts were injected
subcutaneously into CD1 nude mice (Charles River
Laboratories) in a volume of 0.3 mL of phosphate-
buffered saline. Animals were monitored twice a week
for signs of distress or disease, and tumor size was
measured using a caliper. Ex vivo imaging of Venus
fluorescence in dissected tumors was performed on an
IVIS Lumina III platform and analyzed with Living
Image Software, version 4.2 (Caliper Life Sciences).
The average radiant efficiency was calculated based on
the epifluorescence signal as indicated in the user
manual.
Experiments involving animals were performed in
accordance with Italian laws (D.L.vo 116/92 and fol-
lowing additions), which enforces the EU 86/609
directive (Council Directive 86/609/EEC of 24
November 1986 on the approximation of laws, regula-
tions, and administrative provisions of the Member
States regarding the protection of animals used for
experimental and other scientific purposes).
MACROPHAGE DEPLETION IN
VIVO AND CULTURE IN VITRO
To deplete macrophages in vivo, we used the anti–
colony stimulating factor 1 (CSF-1) receptor antibody
(ASF98), a rat monoclonal anti-murine CD115 anti-
body (immunoglobulin G [IgG] 2a) that inhibits
CSF-1–dependent cell growth by blocking the binding
of CSF-1 to its receptor (CSF-1R), the selectivity of
which has been characterized previously.(13) As a con-
trol, we injected an isotype-matched anti-rat IgG (Sig-
ma-Aldrich). Mice were injected intraperitoneally at
doses of 2 mg/mouse.
Clodronate, encapsulated in liposomes, was also
used to deplete macrophages in Mdr22/2 and CD1-
nude mice. Clodronate liposomes were prepared as
described previously.(14) Control liposomes contained
phosphate-buffered saline only. Each animal received
0.01 mL/g (5 mg of clodronate per 1 mL of the
total suspension volume) of clodronate liposomes or
control liposomes via intraperitoneal injection. The
clodronate and control liposomes were obtained from
the Foundation Clodronate Liposomes (Amsterdam,
Netherlands).
The murine macrophage cell line RAW264.7
(ECACC) was grown in DMEM (Lonza) supple-
mented with 10% FBS NA (HyClone), 1% glutamine
(Euroclone) and 1% penicillin/streptomycin (Life
Technologies) under 5% CO2 at 378C. Normal bone
HEPATOLOGY, Vol. 00, No. 00, 2016 RAVA ET AL.
3
marrow macrophages were derived from of C57/BL6
mice (Harlan).(15)
OTHER METHODS
Other protocols and reagents are described in the
Supporting Materials and Methods.
Results
We used a model based on the genetic manipula-
tion of embryonic liver progenitors (hepatoblasts) ex
vivo followed by their adoptive transfer into recipient
mice.(9) Hepatoblasts were isolated from fetal livers at
E14.5-18.5 and transduced with different combina-
tions of retroviruses expressing c-myc, oncogenic Ras
(H-RasV12), or an shRNA targeting p53 (unless
using p53-null cells). As expected,(9) these cells
became immortal in culture and acquired a trans-
formed phenotype, as shown by their ability to gener-
ate liver-derived tumors with histological subtypes(16)
and markers characteristic of human HCC when
injected subcutaneously in immunocompromised
CD-1 nude mice (Supporting Fig. S1A,B). RNA
analysis and immunostaining revealed that ST18 was
expressed in tumors but not in normal liver(1,8) or
transformed hepatoblasts in vitro before injection into
recipient mice (Fig. 1A), indicating that the gene was
induced by tumor-associated microenvironmental
signals.
ST18 is expressed in tumors arising in mice knock-
out for the Abcb4 or Mdr2 gene (henceforth Mdr22/2
mice),(4) a model of inflammation-driven HCC.(17)
Preneoplastic livers in 4- to 10-month-old Mdr22/2
animals also became positive for ST18 (Fig. 1B), sug-
gesting that expression was triggered by chronic
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FIG. 1. ST18 is induced by inflammatory cues in hepatoblasts. (A) Left: Quantitative reverse-transcription PCR analysis of ST18
mRNA levels in adult liver in cell lines derived from mouse liver progenitors (including E14.5 shp53-Myc, E14.5 shp53-RasV12,
E14.5 Myc-RasV12, E18.5 shp53-Myc-RasV12, and E18.5 shp53-RasV12) and in subcutaneous tumors derived from the same cells. *P
5 0.002. **P 5 0.0462. Right: ST18 is expressed in subcutaneous hepatoblast-derived tumors but not normal liver. (B) Hematoxylin
and eosin (H&E) staining shows portal inflammatory infiltrates in preneoplastic Mdr22/2 livers at the indicated ages. Staining of
IHC sections with ST18 antibodies (ST18) shows positivity in Mdr22/2 but not wild-type livers. (C) Hepatic lesions and ST18 posi-
tivity in liver biopsies from PFIC1, PFIC2, and PFIC3 patients. (D) Mouse liver sections 24 hours after LPS treatment showing
irregular hepatocyte arrangement, inflammatory infiltrates, and induction of ST18, in particular nearby blood vessels (arrow) in both
the periportal and centrilobular zones.
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inflammation even before the onset of tumorigenesis.
Mdr22/2 mice lack a P-glycoprotein of the bile cana-
licular membrane, causing defective secretion by hepa-
tocytes of lipids required to neutralize bile salts.(17)
The ensuing high concentration of monomeric bile
salts causes persistent damage of the hepatic epitheli-
um forming the initial bile canaliculi, with the conse-
quent inflammatory response preceding tumor
development.(18-20) These lesions are analogous to
those observed in progressive familial intrahepatic cho-
lestasis (PFIC), a recessive autosomal disorder involv-
ing a chronic hepatic inflammation that progresses to
fatal liver failure during childhood. PFIC comes in
three types—PFIC1, PFIC2, and PFIC3—with muta-
tions in the hepatocyte membrane transporters
ATP8B1, ABCB11, and ABCB4, respectively.(21)
The most severe form, PFIC2, may further progress to
HCC or cholangiocarcinoma.(22) Liver biopsies from
PFIC1, PFIC2, and PFIC3 patients showed expres-
sion of ST18 in the three conditions, clearly above the
levels detected in control tissue (Fig. 1C). Hence,
membrane transporter deficiencies lead to analogous
effects in mice and humans, with chronic inflamma-
tion and induction of ST18 expression.
To further investigate the link between inflamma-
tion and ST18 expression, we induced an acute inflam-
matory response in wild-type C57BL/6 mice by
intraperitoneal injection of bacterial lipopolysaccharide
(LPS).(23) ST18 was induced in the liver 24 hours after
LPS injection, especially nearby blood vessels (Fig.
1D). Thus, either acute or chronic inflammatory con-
ditions could trigger ST18 expression in liver cells,
owing most likely to the exposure to proinflammatory
cytokines or cellular contacts.
Based on above results, we hypothesized that expres-
sion of ST18 in hepatoblast-derived tumors (Fig. 1A)
might be driven by the inflammatory microenvironment
characteristic of many cancers.(10,24) TAMs have been
shown to play important cancer-promoting functions in
a variety of models, including HCC.(25,26) Consistent
with this notion, we observed significant infiltration of
TAMs in mouse hepatoblast–derived tumors, as mea-
sured by immunohistochemistry (IHC) for the pan-
macrophage marker Iba1(27) (Supporting Fig. S1C). To
mimic the interplay between macrophages and liver
cancer cells in vitro, we cocultured transformed hepato-
blasts for 12 hours with either primary bone marrow–
derived macrophages or the macrophage cell line RAW
264.7, and purified back liver cells before RNA isola-
tion. Coculture led to the acute induction of the ST18
mRNA in hepatoblasts, which was further reinforced by
pretreatment of the macrophages with LPS for 1 hour
(Supporting Fig. S1D). Milder activation of the gene
was also observed upon treatment of hepatoblasts with
RAW 264.7 culture supernatants (Supporting Fig.
S1E). Thus, macrophages trigger ST18 induction in liv-
er cells in vitro: this involves at least in part soluble cues,
but remains most effective with cell–cell contacts.
To address the role of ST18 in tumorigenesis, c-
myc– and H-RasV12–transformed p532/2 hepatoblasts
were transduced with an shRNA hairpin targeting the
ST18 mRNA, expressed from the doxycycline-
inducible vector TtRMPVIR.(12) Infected cells were
then sorted for expression of the associated Venus
marker and injected subcutaneously into CD-1 nude
mice. Induction of the shRNA by exposure to doxycy-
cline from the day of seeding (day 0) significantly sup-
pressed tumor development relative to either untreated
mice (shST18 off) or tumors infected with the control
vector (shREN.713) (Supporting Fig. S2A,B). Thus,
expression of ST18 is required for tumor development
in vivo.
We then let tumors develop for 2 weeks before
inducing the knockdown: 4 hours after activation, the
ST18 shRNA caused hemorrhages that extended pro-
gressively from the tumor site to adjacent subcutaneous
areas (Fig. 2A). Dissection and ex vivo imaging 24
hours after shRNA activation revealed hemorrhagic
and friable tumor masses with loss of Venus fluores-
cence relative to untreated controls (Fig. 2B). RNA
analysis and IHC staining confirmed a decrease in
ST18 abundance with residual expression confined to
the progressively reduced nonnecrotic areas (Fig.
2C,D). Similar effects were induced by two other
ST18 shRNAs, but not the shREN.713 control (Sup-
porting Fig. S3A-D). Closer pathological analysis
(Fig. 2E, insets) revealed that in untreated mice, the
subcutaneous tumor mass was consistent with a poorly
differentiated tumor, composed of highly cohesive
atypical cells. Doxycycline-treated tumors showed
severe intratumoral hemorrhages and necrotic areas
that increased over time. Cells became multifocally less
cohesive, arranged in bundles, and spindle-shaped.
Staining with the vascular endothelial cell marker VE-
cadherin(28) revealed a dilatation of intratumoral blood
vessels (ectasia), coincident with a decrease in Ki67
and appearance of cleaved caspase-3, none occurring
with the control shRNA (Supporting Fig. S4A,B).
Altogether, silencing of ST18 led to proliferative arrest
and induction of apoptosis, concomitant with vascular
ectasia and hemorrhage: these combined effects are all
likely to contribute to acute tumor regression.
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Knockdown of ST18 in liver cancer cells also led to a
rapid loss of TAMs in subcutaneous tumors, residual
IBA11 cells showing dramatic changes in morphology
suggestive of impaired functionality (Supporting Fig.
S4C, D). Importantly, TAMs themselves did not express
ST18, and our experimental system ensures hepatocyte-
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FIG. 2. Expression of ST18 is required for tumor maintenance. (A) Hemorrhages initiating from the tumor and extending to the
adjacent subcutaneous areas were noticeable 4 hours after ST18 silencing and increased progressively throughout the indicated time
course. All experiments were performed using induction of the shST18-6 hairpin with administration of doxycycline (at time 0) by
way of oral gavage. (B) Left: Ex vivo fluorescent imaging of tumors dissected from either untreated recipient mice or 24 hours after
doxycycline administration. The fluorescent Venus marker was constitutively expressed from the same TtRMPVIR vector(12) express-
ing doxycycline-inducible shST18; loss of fluorescence after ST18 knockdown is thus due to loss of the targeted cells. Right: quantifi-
cation of average radiant efficiency in the same tumors shown at left. **P 5 0.0013. (C) Quantitative reverse-transcription PCR
analysis of ST18 mRNA levels in tumors confirmed knockdown 4 hours after shST18 induction. (D) Induction of shST18 induced
hemorrhages and necrosis concomitant with a progressive decrease of ST18 expression. Insets denote that in untreated mice, the
tumor was composed of highly cohesive atypical cells; in doxycycline-treated tumors, cells were multifocally less cohesive, arranged in
bundles, and spindle-shaped. Scale bars 5 100 lm.
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specific knockdown. Thus, the maintenance of TAMs
relied on sustained expression of ST18 in cancer cells.
To further investigate the interplay between ST18
expression in hepatoblasts, TAMs and tumor mainte-
nance, we predepleted macrophages systemically in
recipient animals by intraperitoneal injection of a
monoclonal antibody that blocks the murine CSF-1
receptor (or CD115)(13) or isotype-matched IgG as
control. Anti–CD-115 effectively caused selective
depletion of circulating CD1151 cells 4 days after
injection, with no effects on LY6G1 neutrophils (Fig.
3A). At this stage (day 0, Fig. 3B), transformed hepa-
toblasts were injected subcutaneously: examination of
the animals over time revealed continued depletion of
circulating CD1151 monocytes/macrophages (Fig.
3B) associated with a significant delay in tumor devel-
opment (Fig. 3C). At day 15, CD1151 cell numbers
were minimal and tumors virtually undetectable. At
the last time point (day 24), partial recovery of circulat-
ing CD1151 cells (Fig. 3B) was accompanied by the
growth of small tumor masses (Fig. 3C); relative to
untreated controls, however, these tumors still lacked
macrophages (assessed by way of IBA1 staining),
failed to induce ST18, and showed elevated apoptosis
(Fig. 3D). These findings suggest that macrophages
are required for ST18 induction and tumor
development.
We then addressed the effect of macrophage deple-
tion in preformed tumors by injecting anti-CD115 or
control IgG in tumor-bearing animals. Four hours
after treatment, loss of IBA11 cells was accompanied
by down-regulation of ST18 with intratumoral and
subcutaneous hemorrhages (Fig. 3E,F). As an inde-
pendent means to deplete macrophages, we injected
liposome-encapsulated clodronate.(14) Again, loss of
IBA11 cells coincided with dramatic changes in tumor
morphology, with necrosis, hemorrhage, loss of ST18
expression, and induction of apoptosis (Supporting
Fig. S5A). Finally, we injected clodronate in preneo-
plastic and neoplastic Mdr22/2 animals, once again
causing the parallel loss of IBA1 and ST18 staining
(Supporting Fig. S5B,C). Altogether, we conclude
that TAMs are required both for ST18 expression in
cancer cells and tumor development/maintenance.
To complement our findings, we addressed the
function of ST18 in the human HCC cell line HepG2
because, unlike mouse hepatoblasts, these cells
expressed ST18 constitutively in the absence of inflam-
matory stimuli.(4) ST18 knockdown in cultured
HepG2 cells induced cell death (Supporting Fig. S6A,
B), indicating a cell-autonomous requirement for
ST18. As with mouse hepatoblasts, induction of the
shRNA in subcutaneous HepG2 tumors caused intra-
tumoral hemorrhages and tumor regression (Support-
ing Fig. S6C-E).
We finally profiled ST18-dependent gene expres-
sion in our mouse model. RNA sequencing of control
and ST18-depleted tumors (analyzed 4 hours follow-
ing induction of shST18-6) allowed us to identify 677
and 467 up-regulated and down-regulated genes,
respectively (Supporting Tables S1 and S2). The latter
included known inflammation-related genes, such as
members of the nuclear factor kappa B (NF-kB) family
of transcription factors, as well as inflammatory cyto-
kines and chemokines (most notably Ccl2) that are
known to control the recruitment and activation of
myeloid cells to the tumor sites (Fig. 4A).(29-33) Gene
set enrichment analysis (Supporting Tables S3 and S4)
showed that ST18 knockdown led to the down-
regulation of inflammation-associated genes, including
in particular a set of genes up-regulated in hepatic stel-
lar cells after stimulation with LPS(34) (Fig. 4B) as well
as genes containing the binding motif for the inflam-
matory transcription factor NF-kB (Fig. 4C). Use of
Ingenuity pathway analyzer software further pointed to
a role of the transcription factor NF-kB in the regula-
tion of ST18-dependent genes (Fig. 4C). Immunos-
taining analysis of the NF-kB subunits P65 and P50
revealed rapid decreases in the levels of both proteins
after ST18 knockdown (Fig. 4D,E) a result confirmed
for p65 in macrophage-depleted tumors (Fig. 4E,
Anti-CD115). Although the mechanisms linking
ST18 and NF-kB activities remain to be addressed,
and indirect effects due to macrophage loss cannot be
excluded at this stage, these data point to a role of
ST18 upstream of NF-kB in controlling the transcrip-
tional response of liver cells to inflammatory cues,
thereby sustaining the mutual interaction between
tumor cells and TAMs.
Discussion
Previous observations, including L1 insertional
mutagenesis in human HCC, as well as gene amplifi-
cation and activation in inflammation-driven HCC
nodules in Mdr22/2 mice, pointed to ST18 as a candi-
date oncogene in HCC.(4) However, direct evidence
for a role of ST18 in cancer was missing altogether.
Using a mouse model of HCC based on ex vivo trans-
formation and adoptive transfer of liver progenitor cells
(hepatoblasts),(9) we demonstrate that ST18 is
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FIG. 3. Depletion of macrophages in
vivo prevents ST18 expression in hepato-
blasts and affects both tumor development
and maintenance. (A) Fluorescence-
activated cell sorting of macrophages
(CD1151) and neutrophils (LY6G1) in
peripheral blood 4 days after injection of
mice with anti-CD115 (1), compared
with injection of control IgG (2). The
data represent the average and standard
deviation for three mice. *P 5 0.01. Cell
numbers are expressed relative to total
white blood cells. (B) Analysis of
CD1151 cell numbers over time in one
of the above animals (note that day 0
here is the 4th day after anti-CD115
treatment (i.e., the same time point ana-
lyzed in panel A). (C) Left: Tumor vol-
umes in mice pretreated with either
control IgG (2) or anti-CD115 (1) at
days 15 and 24 after tumor seeding.
Right: Photographs of tumors dissected
(at day 24) from carriers pretreated with
IgG (control) or anti-CD1151, as indi-
cated. (D) Hematoxylin and eosin
(H&E) and IHC staining for the indicat-
ed proteins (IBA1, ST18, cleaved cas-
pase-3) reveal hemorrhage, macrophage
depletion, lack of ST18 expression, and
increased apoptosis in tumors arising in
anti-CD115–treated mice compared with
IgG-treated mice. (E) Hematoxylin and
eosin (H&E) and IHC staining 8 hours
after anti-CD115 or control IgG injection
in established tumors revealed effects
analogous to the above, including intratu-
moral hemorrhage and necrosis (H&E),
decreased ST18 expression, and, as
expected, loss of IBA11 macrophages.
The mean numbers of IBA11 cells in
four different microscopic fields in anti-
CD115 and IgG-injected tumors are
shown. **P < 0.0001. Scale bars 5 100
lm. (F) Subcutaneous hemorrhages were
noticeable as early as 4 hours after anti-
CD115 injection in established tumors
and became more severe over time.
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important for tumor development and maintenance.
Detailed analysis revealed an unexpected mode of
action for ST18, as a central component in a feed-
forward loop between neoplastic epithelial cells and
TAMs.
The ST18 mRNA and protein were undetectable in
either normal liver(1,8) or cultured hepatoblasts but
were expressed in subcutaneous tumors derived from
the same cells. These results led us to hypothesize that
ST18 expression in vivo may require tumor-derived
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FIG. 4. ST18 knockdown in
hepatoblast-derived tumors
affects inflammation- and NF-
kB–associated genes. RNA
sequencing was used to identify
genes whose expression was
affected 4 hours after induction
of ST18 knockdown with the
shST18-6 hairpin in subcutane-
ous tumors, with three mice per
condition. (A) Genes involved
in NF-kB signaling and/or pos-
itive regulation of myeloid cell
activity that showed ST18-
dependent expression. (B) Gene
set enrichment analysis revealed
that genes induced by LPS in
hepatic stellar cells (gene set
SEKI_INFLAMMATORY_R-
ESPONSE_LPS_UP)(34) were
down-regulated after ST18
knockdown. The heatmap
shows the relative expression of
the mRNAs included in this
gene set in hepatoblast-derived
tumors, without (untreated) or
with (4h Doxy) ST18 knock-
down (three independent sam-
ples for each condition). (C)
Gene set enrichment analysis
revealed that genes containing
the NF-kB binding motif
(V$NFKAPPAB_01) were
down-regulated after ST18
knockdown. (D) Ingenuity
pathway analyzer software
pointed to a central role of NF-
kB in the regulation of ST18-
dependent genes. (E) IHC
staining of the NF-kB subunits
P65 and P50 revealed rapid
decreases in the levels of both
proteins after ST18 knockdown.
(F) Immunofluorescent detec-
tion of the NF-kB subunit P65
revealed its rapid decrease in
hepatoblast-derived tumors after
ST18 knockdown and macro-
phage depletion.
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microenvironmental signals and in particular inflam-
matory infiltrates, a recurrent feature in solid
tumors.(10,26) In line with this concept, hepatoblast-
derived tumors contained infiltrating macrophages, the
ablation of which led to rapid down-regulation of
ST18 in the tumor cells. Furthermore, ST18 could be
induced in liver cells, either in vitro by coculture with
macrophages or in vivo by exposure to inflammatory
conditions. Taken together, these findings indicate
that ST18 expression in tumors is triggered by inflam-
matory cues emanating from TAMs.
The role of ST18 in tumor cells was addressed
through inducible knockdown of the gene in the trans-
duced hepatoblasts; this led to rapid tumor involution
associated with a series of adverse events (see below),
including a marked loss of TAM infiltrates. This
mutual dependency between expression of ST18 in
hepatoblasts and maintenance of TAMs pointed to a
regulatory loop between both cell types, with a central
role in tumor maintenance. Indeed, the alternative
modalities of intervention used in our experiments—
ST18 knockdown in tumor cells versus ablation of
TAMs—had strikingly similar consequences. Both
treatments suppressed tumor progression (compare
Supporting Fig. S2 and Fig. 3C,D) or, if applied to
preformed tumors, caused rapid tumor involution asso-
ciated with loss of TAMs (Supporting Fig. S4C,D and
Fig. 3E), down-regulation of ST18 (Figs. 2D and 3E),
proliferative arrest, and apoptosis in the tumor cells
(Supporting Fig. S4A and Fig. 3D), as well as perva-
sive hemorrhage, spreading from the tumor into the
adjacent subcutaneous areas (Figs. 2A and 3F).
The precise origin of the TAMs infiltrating subcuta-
neous tumor lesions remains to be determined. Like
most tissues, both the liver and the skin are home to
resident macrophage populations, which are intimately
linked to tissue homeostasis and recruit blood mono-
cytes when damage occurs.(26,35) At the steady state,
most tissue-resident macrophage populations (with
some notable exception such as the intestine and, to
some extent, the liver) are originated during embryonic
development by yolk sac–derived precursors, with min-
imal contribution from adult bone marrow hematopoi-
esis. The contribution of circulating monocytes to the
resident macrophage pool is instead dominant in
inflammatory contexts, such as infection and
cancer.(33,35-38)
The origin of TAMs notwithstanding, a large body
of literature indicates that these cells—in particular in
the M2 polarized state—tend to have strong protu-
moral activities in most cancer types.(26,29) In HCC, in
particular, TAM infiltration was shown to correlate
with poor prognosis.(39) Our macrophage-depletion
experiments with anti-CD115 or Clodronate directly
support this notion and are consistent with previous
observations in glioblastoma and breast cancer(29,40,41);
however, it remains to be addressed whether TAMs
may also elicit expression of ST18 in those tumors.
Reciprocally, whether ST18 controls TAM function
elsewhere than in the liver remains unclear. It is note-
worthy here that TAMs can either promote or antago-
nize tumor growth,(29) which may conceivably also
explain the contrasting roles attributed to ST18 in can-
cer.(1-4)
The signaling pathways through which TAMs elicit
ST18 expression in tumor cells, and ST18 in turn
feeds back to TAMs, also remain to be unraveled. Our
RNA sequencing analysis indicated that ST18 might
regulate part of the transcriptional response to inflam-
matory signals in hepatoblasts, in particular through its
requirement for NF-kB activation. Indeed, among the
genes showing ST18-dependent expression in our
tumor model, we found a number of known NF-kB
regulated genes that may have a direct role in TAM
homeostasis; for example, CCL2 and Cxcl2 are both
involved in the recruitment of inflammatory monocytes
(and myeloid cells) to tumors.(32,33,42) Other proin-
flammatory cytokines such as interleukin-1b, interleu-
kin-6, and CSF-3 have been shown to control the
phenotype of tumor-elicited myeloid cells.(43,44)
Although not investigated experimentally in this study,
the reduced expression levels of these cytokines in
ST18-depleted tumors supports a model whereby (1)
TAMs derive from circulating monocytes in our tumor
model and (2) ST18 controls the expression of critical
environmental factors that control the recruitment/
activation of TAMs.
An essential question raised by our study pertains to
the primary outputs of the aforementioned regulatory
loop in tumor maintenance, with two extreme—albeit
not exclusive—possibilities. First, ST18 may have an
intrinsic (i.e., cell-autonomous) role in proliferation and
survival of tumor cells, as suggested by our in vitro data
on the HepG2 cell line. In this setting, the tumorigenic
properties of TAMs in the liver would rely at least in
part on their ability to elicit ST18 expression in tumor
cells. Second, ST18 may act mainly in a nonautono-
mous manner, allowing the maintenance of TAMs,
which in turn signal tumor cell proliferation/survival.
This cell-extrinsic effect of ST18 on TAMs may thus
be an important, if not the principal determinant of its
tumor-promoting activity in the liver.(4)
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In either of the above scenarios, our findings
lend further support to the concept that macrophage
targeting may be an effective therapeutic strategy
in liver cancer.(26) Among others, macrophage deple-
tion enhanced the antitumoral effects of the kinase
inhibitor sorafenib,(45) and the chemotherapeutic
agent trabectedin acted in part through its toxic effect
of TAMs.(46) Consequently, elucidation of the molec-
ular mechanisms through which ST18 mediates
epithelium–macrophage interactions bears significant
potential for future therapeutic development.
Finally, the mutual relationship between macro-
phages and epithelial cells in liver tumorigenesis, as well
as the involvement of ST18—and possibly NF-kB—in
this process may have important counterparts in tissue
homeostasis. Indeed, clodronate-mediated depletion of
Kupffer cells impaired liver regeneration upon partial
hepatectomy due to loss of NF-kB activation.(47) In the
same conditions, direct inhibition of NF-kB in hepato-
cytes increased apoptosis and decreased proliferation.(48)
It will thus be interesting to address whether Kupffer
cells mediate the activation of ST18 in the regenerating
liver epithelium and whether ST18 is required for acti-
vation of NF-kB after partial hepatectomy. It is tempt-
ing to speculate that this role of ST18 may extend to
other tissues, representing perhaps a conserved element
of macrophage–epithelium interactions.
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